A Phase 2 interventional study of In Vivo Exposure Therapy and Virtual Reality Exposure Therapy in Height Phobia, sponsored by CAMC Health System. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by CAMC Health System · Phase 2, Interventional, and Treatment
Lack of enrollment, 5 completed by 2011 however no further enrollment took place until study terminated in 2017.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study will determine the effects of D-Cycloserine (DCS) on fear reduction in patients diagnosed with phobia of heights (acrophobia) undergoing one session of three hours of virtual reality exposure therapy (VRET) or in vivo exposure therapy (IVET).
The impact of D-Cycloserine on Virtual Reality Exposure Therapy (VRET) and In Vivo Exposure Therapy (IVET) for phobia of heights (acrophobia) will be tested using a randomized, double-blind, placebo-controlled trial. Eighty participants will be randomly assigned to one of the four treatment conditions: one-session VRET (3 hours) and 50 mg D-Cycloserine (VR-OST + DCS, N1=20); one-session VRET (3 hours) and placebo (VR-OST + Pl, N2=20); one-session IVET (3 hours) and placebo (IV + Pl, N3=20); or one-session IVET (3 hours) and 50 mg D-Cycloserine, (IV + DCS, N4=20). For twenty participants (5 from each group) the treatment will be delayed for three weeks and an additional assessment will be conducted as they will comprise a Wait List (WL) control group. Behavioral, cognitive and physiological changes in acrophobia will be assessed at pre-treatment, post-waitlist, post-treatment and 3 months follow-up.
22 studies on the registry are indexed under Acrophobia; none are open to participants now.
This study's enrollment of 4 is below the median of 60 across 22 interventional studies indexed under Acrophobia.
Browse Acrophobia studies →CAMC Health System is the lead sponsor of 47 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: In Vivo Exposure Therapy · Drug: D-Cycloserine
Behavioral: Virtual Reality Exposure Therapy · Drug: D-Cycloserine
Behavioral: Virtual Reality Exposure Therapy · Drug: Placebo
Behavioral: In Vivo Exposure Therapy · Drug: Placebo
Three hours of exposure therapy in a high place
Three hours of exposure therapy using a virtual reality system
50 mg of DCS administered 30 minutes before the session
Also known as: Seromycin
50 mg placebo administered 30 minutes before the session
Specific Phobia (Acrophobia) Diagnosed Based on Anxiety Disorders Interview Schedule - IV (ADIS-IV)
Presence or absence of a diagnosis of specific phobia (acrophobia) as assessed using the Anxiety Disorders Interview Schedule-IV (ADIS-IV).
Time frame: One-week post-treatment and 3-months follow-up
Physiological Responses to Phobia-related Stimuli, Percentage of Steps Completed and Subjective Units of Distress During a Behavioral Avoidance Test (BAT)
Physiological responses to phobia-related stimuli, percentage of steps completed and Subjective Units of Distress during a Behavioral Avoidance Test (BAT) - Study was terminated due to lack of enrollment and outcome data are unavailable
Time frame: One-week post-treatment and 3-months follow-up
Number of Steps Completed During the Behavioral Analysis Test (BAT)
Number of steps completed during exposure to the feared stimulus. Higher numbers will indicate greater completion of the BAT procedure at the assessment
Time frame: One-week post-treatment and 3-months follow-up
Subjective Units of Distress (SUDS) During BAT
Participant-supported SUDS ratings to be obtained during BAT to assess distress associated with exposure to the feared stimulus
Time frame: One-week post-treatment and 3-months follow-up
Patients will be either self referred based on ads posted in local newspapers or referred by their primary physician to the WVU Behavioral Medicine and Psychiatry Department (CAMC) for treatment of flying or height phobia. Upon referral, a brief phone screening interview assessing phobic status and relevant medical history will be conducted by the principal investigator
| Milestone | IVET+DCS | VRET+DCS | VRET+Placebo | IVET+Placebo | Wait-List |
|---|---|---|---|---|---|
| Started | 1 | 1 | 1 | 1 | 1 |
| Completed | 1 | 1 | 1 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Presence or absence of a diagnosis of specific phobia (acrophobia) as assessed using the Anxiety Disorders Interview Schedule-IV (ADIS-IV).
| Participants | IVET+DCS | VRET+DCS | VRET+Placebo | IVET+Placebo | Wait-List |
|---|---|---|---|---|---|
| Specific Phobia (Acrophobia) Diagnosed Based on Anxiety Disorders Interview Schedule - IV (ADIS-IV) | 0 | 0 | 0 | 0 | 0 |
Physiological responses to phobia-related stimuli, percentage of steps completed and Subjective Units of Distress during a Behavioral Avoidance Test (BAT) - Study was terminated due to lack of enrollment and outcome data are unavailable
| Participants | IVET+DCS | VRET+DCS | VRET+Placebo | IVET+Placebo | Wait-List |
|---|---|---|---|---|---|
| Physiological Responses to Phobia-related Stimuli, Percentage of Steps Completed and Subjective Units of Distress During a Behavioral Avoidance Test (BAT) | 0 | 0 | 0 | 0 | 0 |
Number of steps completed during exposure to the feared stimulus. Higher numbers will indicate greater completion of the BAT procedure at the assessment
| Participants | IVET+DCS | VRET+DCS | VRET+Placebo | IVET+Placebo | Wait-List |
|---|---|---|---|---|---|
| Number of Steps Completed During the Behavioral Analysis Test (BAT) | 0 | 0 | 0 | 0 | 0 |
Participant-supported SUDS ratings to be obtained during BAT to assess distress associated with exposure to the feared stimulus
| Participants | IVET+DCS | VRET+DCS | VRET+Placebo | IVET+Placebo | Wait-List |
|---|---|---|---|---|---|
| Subjective Units of Distress (SUDS) During BAT | 0 | 0 | 0 | 0 | 0 |
Collected over One-week post-treatment and 3 months follow-up. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IVET+DCS | — | — | — |
| VRET+DCS | — | — | — |
| VRET+Placebo | — | — | — |
| IVET+Placebo | — | — | — |
| Wait-List | — | — | — |
| Age, Categorical(Participants) | IVET+DCS | VRET+DCS | VRET+Placebo | IVET+Placebo | Wait-List | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | IVET+DCS | VRET+DCS | VRET+Placebo | IVET+Placebo | Wait-List | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 |
Ran from Jul 2009 to primary completion in Feb 2012, 31 months.
Results were first posted in Oct 2026, 14 years 8 months after primary completion.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Dec 2014 → Feb 2012 and completion Dec 2014 → Jun 2017.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Lack of enrollment, 5 completed by 2011 however no further enrollment took place until study terminated in 2017.
Lack of enrollment, 5 completed by 2011 however no further enrollment took place until study terminated in 2017.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cycloserine
CAMC Health System